BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nerandomilast (Jascayd) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nerandomilast (Jascayd)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06195072-10645@assetmemo.bio
DTSTAMP:20261121T005411Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Nerandomilast (Jascayd): Phase 2 readout est. (NCT06195072)
DESCRIPTION:Nerandomilast (Jascayd)\, phase 2.\nStudy: Platform Clinical St
 udy for Conquering Scleroderma\nEstimated primary completion: November 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/nerandomilast-jasc
 ayd#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06195072
URL:https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06806592-10645@assetmemo.bio
DTSTAMP:20261121T005411Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Nerandomilast (Jascayd): Phase 3 readout est. (NCT06806592)
DESCRIPTION:Nerandomilast (Jascayd)\, phase 3.\nStudy: A Study to Test Whet
 her Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Dis
 eases\nEstimated primary completion: 15 April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06806592
URL:https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06238622-10645@assetmemo.bio
DTSTAMP:20261121T005411Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:Nerandomilast (Jascayd): Phase 3 readout est. (NCT06238622)
DESCRIPTION:Nerandomilast (Jascayd)\, phase 3\, Idiopathic Pulmonary Fibros
 is.\nStudy: A Follow-up Study to Test Long-term Treatment With Nerandomila
 st in People With Pulmonary Fibrosis Who Took Part in a Previous Study Wit
 h Nerandomilast\nEstimated primary completion: 28 April 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06238622
URL:https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07570888-10645@assetmemo.bio
DTSTAMP:20261121T005411Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nerandomilast (Jascayd): Phase 4 readout est. (NCT07570888)
DESCRIPTION:Nerandomilast (Jascayd)\, phase 4.\nStudy: This is a Trial Desi
 gned to Evaluate the Combination of Nerandomilast With Mycophenolate Acros
 s a Wide Variety of Pulmonary Fibrosis Subtypes\, With the Aim of Providin
 g Clinicians With Assurance That This is an Appropriate Therapeutic Combin
 ation.\nEstimated primary completion: June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07570888
URL:https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07321860-10645@assetmemo.bio
DTSTAMP:20261121T005411Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nerandomilast (Jascayd): Phase 2/3 readout est. (NCT07321860)
DESCRIPTION:Nerandomilast (Jascayd)\, phase 2/3.\nStudy: This Study Evaluat
 es the Safety\, Target Engagement\, and Preliminary Efficacy of Galunisert
 ib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) i
 n GREM2-positive ALS\, a Biomarker-defined Subgroup Hypothesized to Reflec
 t Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling\nEstimat
 ed primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nerandomilast-jascayd#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07321860
URL:https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07540988-10645@assetmemo.bio
DTSTAMP:20261121T005411Z
DTSTART;VALUE=DATE:20281205
DTEND;VALUE=DATE:20281206
SUMMARY:Nerandomilast (Jascayd): Phase 3 readout est. (NCT07540988)
DESCRIPTION:Nerandomilast (Jascayd)\, phase 3.\nStudy: FIBRONEER-ACT: A Stu
 dy to Test Whether Nerandomilast Helps People With Fibrosing Interstitial 
 Lung Disease at Risk for Disease Progression\nEstimated primary completion
 : 5 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ne
 randomilast-jascayd#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07540988
URL:https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07366034-10645@assetmemo.bio
DTSTAMP:20261121T005411Z
DTSTART;VALUE=DATE:20290427
DTEND;VALUE=DATE:20290428
SUMMARY:Nerandomilast (Jascayd): Phase 3 readout est. (NCT07366034)
DESCRIPTION:Nerandomilast (Jascayd)\, phase 3.\nStudy: A Study to Find Out 
 How Nerandomilast is Tolerated\, Handled by the Body\, and if it Helps Chi
 ldren and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)\nEs
 timated primary completion: 27 April 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07366034
URL:https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07201922-10645@assetmemo.bio
DTSTAMP:20261121T005411Z
DTSTART;VALUE=DATE:20290514
DTEND;VALUE=DATE:20290515
SUMMARY:Nerandomilast (Jascayd): Phase 3 readout est. (NCT07201922)
DESCRIPTION:Nerandomilast (Jascayd)\, phase 3.\nStudy: A Study to Test Whet
 her Nerandomilast Can Help Slow Down Changes in the Lung in People With a 
 Family History of Pulmonary Fibrosis\nEstimated primary completion: 14 May
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/nerandomilast-
 jascayd#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07201922
URL:https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07497087-10645@assetmemo.bio
DTSTAMP:20261121T005411Z
DTSTART;VALUE=DATE:20300226
DTEND;VALUE=DATE:20300227
SUMMARY:Nerandomilast (Jascayd): Phase 3 readout est. (NCT07497087)
DESCRIPTION:Nerandomilast (Jascayd)\, phase 3\, Systemic Sclerosis.\nStudy:
  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosi
 s\nEstimated primary completion: 26 February 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07497087
URL:https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07789015-10645@assetmemo.bio
DTSTAMP:20261121T005411Z
DTSTART;VALUE=DATE:20300321
DTEND;VALUE=DATE:20300322
SUMMARY:Nerandomilast (Jascayd): Phase 3 readout est. (NCT07789015)
DESCRIPTION:Nerandomilast (Jascayd)\, phase 3.\nStudy: A Study to Understan
 d How Nerandomilast Works in People With Active Idiopathic Inflammatory My
 opathies\nEstimated primary completion: 21 March 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07789015
URL:https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
